ClinicalTrials.gg
CompletedNCT07797192HRIPT + FOTOUpdated Sep 16, 2026

Evaluation of Allergenicity by HRIPT and Phototest

An interventional study of Blancy Pro in Safety, sponsored by Brainfarma Industria Química e Farmacêutica S/A. Completed at 1 site in Brazil. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Brainfarma Industria Química e Farmacêutica S/A (part of Hypera Pharma) · Not applicable, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This clinical study will evaluate the dermatological safety and allergenic potential of a cosmetic product. The study will use the Human Repeat Insult Patch Test (HRIPT) and phototest procedures to assess whether the product may cause skin irritation, allergic reactions, photoirritation, or photosensitization after repeated use and exposure to ultraviolet light.

Participants will receive applications of the investigational product under controlled conditions and will undergo dermatological evaluations throughout the study. The results will help determine the product's skin compatibility and safety for consumer use.

Read the detailed description

This is a single-center, single-blind, non-comparative clinical study designed to evaluate the dermal compatibility and allergenic potential of an investigational cosmetic product using the Human Repeat Insult Patch Test (HRIPT) and phototest procedures.

The HRIPT phase will assess primary dermal irritation, cumulative irritation, and skin sensitization potential through repeated applications of patches containing the investigational product to the participants' backs under maximized conditions. The practical phase lasts six weeks and includes three weeks of product application, two weeks of rest, and one challenge week with product reapplication on a previously untreated skin site.

The phototest phase will assess the photoirritant and photosensitizing potential of the investigational product following controlled exposure to ultraviolet radiation. Product-containing patches will be applied to the skin and, after removal, the test sites will undergo controlled ultraviolet irradiation. The practical phase lasts five weeks and includes induction, rest, and challenge phases.

Dermatological evaluations will be performed according to standardized criteria, including assessments based on the International Contact Dermatitis Research Group (ICDRG) scale, to confirm the absence of clinically significant irritant, allergenic, photoirritant, or photosensitizing reactions.

02

Conditions studied

  • Safety

Keywords

  • HRIPT
  • Phototest
03

In context

Lead sponsor

Brainfarma Industria Química e Farmacêutica S/A is the lead sponsor of 15 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female participants aged 18 to 70 years.
  • Fitzpatrick skin phototypes I, II, III, or IV.
  • Intact skin at the application site.
  • Willingness to comply with all study procedures and attend scheduled clinic visits for medical assessments, patch applications, and patch readings.
  • Ability to understand the study requirements, provide written , and sign the Informed Consent Form (ICF).

For the phototest procedure, only participants with Fitzpatrick skin phototypes II and III will be eligible.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding women, or women at risk of becoming pregnant during the study.
  • Use of anti-inflammatory medications within 30 days prior to screening or medications within 3 months prior to screening.
  • Immunosuppression due to medication use or active disease.
  • Uncontrolled endocrine disorders.
  • Personal history of atopy.
  • Intense sun exposure or tanning sessions within 15 days prior to assessment or during the study period.
  • Planned intense sun exposure or tanning sessions during the study period.
  • Planned sea bathing, swimming pool use, or sauna sessions during the study period.
  • Participation in water sports during the study period.
  • Dermographism.
  • Use of oral or topical vitamin A acid (retinoids) or related derivatives within 1 week prior to study initiation.
  • Aesthetic and/or dermatological body treatments within 3 weeks prior to screening.
  • Scheduled vaccination during the study period or within 3 weeks prior to screening.
  • History of sensitization, irritation, or photosensitization to topical products.
  • Active local or generalized skin diseases that may interfere with study assessments.
  • Skin hyperreactivity.
  • Initiation of new medications during the study period.
  • Previous participation in studies involving the same product.
  • Congenital or acquired immunodeficiency.
  • Relevant medical history or current evidence of alcohol or substance abuse.
  • Known or suspected intolerance to any ingredient contained in the investigational or comparator products.
  • History of poor compliance or unwillingness to comply with the study protocol.
  • Employees of the study site, sponsor, or their immediate family members directly involved in the study.
  • Any other condition that, in the investigator's opinion, may interfere with study participation or justify exclusion from the study.

Additional Exclusion Criteria for the Phototest:

  • History of diseases aggravated or triggered by ultraviolet radiation.
  • Use of photosensitizing medications.
  • History or current presence of photodermatoses.
  • Personal or family history of skin cancer.
  • Presence of precancerous skin lesions, including melanocytic nevi or actinic keratoses, that may interfere with study assessments.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Investigational Cosmetic Product

    Participants will undergo Human Repeat Insult Patch Test (HRIPT) and phototest procedures using the investigational cosmetic product to evaluate dermatological safety, skin irritation, skin sensitization, photoirritation, and photosensitization potential.

    Other: Blancy Pro

Interventions

  • OtherBlancy Pro

    Blancy Pro is a cosmetic product evaluated for dermatological safety, skin sensitization, photoirritation, and photosensitization potential. Participants will undergo Human Repeat Insult Patch Test (HRIPT) and phototest procedures involving repeated applications of the product under controlled conditions, followed by dermatological assessments to evaluate skin compatibility and the absence of allergenic reactions.

06

What researchers measure

Primary outcomes

  1. Dermal Irritation Assessed by Human Repeat Insult Patch Test (HRIPT) Using ICDRG Criteria

    Dermal irritation following application of Blancy Pro will be assessed using the Human Repeat Insult Patch Test (HRIPT). Patches containing the investigational product and control patches (saline solution, mineral oil, patch without product, and adhesive tape control) will be applied to the lateral back. Skin reactions will be evaluated 48 hours (Day 3) and 96 hours (Day 5) after application according to the International Contact Dermatitis Research Group (ICDRG) grading scale. Skin reactions will be graded according to the International Contact Dermatitis Research Group (ICDRG) criteria, ranging from 0 (negative reaction) to 4 (strong positive reaction). Higher grades indicate greater skin reactivity.

    Time frame: Day 3 and Day 5

  2. Cumulative Dermal Irritation Assessed by Human Repeat Insult Patch Test (HRIPT) Using ICDRG Criteria

    Cumulative dermal irritation following repeated applications of Blancy Pro will be assessed using the Human Repeat Insult Patch Test (HRIPT). Patches containing the investigational product and control materials will be repeatedly applied to the lateral back over a 3-week induction period. Skin reactions will be evaluated 15 to 30 minutes after patch removal and graded according to the International Contact Dermatitis Research Group (ICDRG) criteria. Skin reactions will be graded according to the International Contact Dermatitis Research Group (ICDRG) criteria, ranging from 0 (negative reaction) to 4 (strong positive reaction). Higher grades indicate greater skin reactivity.

    Time frame: Day 3, Day 5, Day 8, Day 10, Day 12, Day 15, Day 17, and Day 19

  3. Dermal Sensitization Assessed by Human Repeat Insult Patch Test (HRIPT) Challenge Phase Using ICDRG Criteria

    Dermal sensitization following repeated application of Blancy Pro will be assessed during the Human Repeat Insult Patch Test (HRIPT) challenge phase. After a two-week rest period, patches containing the investigational product and control materials will be applied to previously unexposed skin sites. Skin reactions will be evaluated 15 to 30 minutes after patch removal and graded according to the International Contact Dermatitis Research Group (ICDRG) criteria. Skin reactions will be graded according to the International Contact Dermatitis Research Group (ICDRG) criteria, ranging from 0 (negative reaction) to 4 (strong positive reaction). Higher grades indicate greater skin reactivity.

    Time frame: Day 38 and Day 39

  4. Dermal Photoirritation Assessed by Phototest Using ICDRG Criteria

    Dermal photoirritation following application of Blancy Pro will be assessed using phototest procedures. Patches containing the investigational product and control materials (saline solution, mineral oil, patch without product, and adhesive tape control) will be applied to the medial back. After 24 hours, patches will be removed, skin reactions will be assessed, and the test sites will be exposed to ultraviolet A (UVA) radiation at a dose of 5 J/cm². Additional assessments will be performed 48 hours after irradiation according to the International Contact Dermatitis Research Group (ICDRG) grading criteria. Skin reactions will be graded according to the International Contact Dermatitis Research Group (ICDRG) criteria, ranging from 0 (negative reaction) to 4 (strong positive reaction). Higher grades indicate greater skin reactivity.

    Time frame: Day 2 and Day 4

  5. Dermal Photosensitization Assessed by Phototest Induction Phase Using ICDRG Criteria

    Dermal photosensitization following repeated application of Blancy Pro and controlled ultraviolet A (UVA) exposure will be assessed during the phototest induction phase. Patches containing the investigational product and control materials will be applied to the medial back and irradiated with UVA at a dose of 5 J/cm². Skin reactions will be evaluated 15 to 30 minutes after patch removal and graded according to the International Contact Dermatitis Research Group (ICDRG) criteria. Skin reactions will be graded according to the International Contact Dermatitis Research Group (ICDRG) criteria, ranging from 0 (negative reaction) to 4 (strong positive reaction). Higher grades indicate greater skin reactivity.

    Time frame: Day 2, Day 4, Day 5, Day 8, Day 10, and Day 12

  6. Dermal Photosensitization Assessed by Phototest Challenge Phase Using ICDRG Criteria

    Dermal photosensitization following repeated application of Blancy Pro will be assessed during the phototest challenge phase. After a two-week rest period, patches containing the investigational product and control materials will be applied to two previously unexposed skin sites. One test area will be irradiated with ultraviolet A (UVA) radiation at a dose of 5 J/cm². Skin reactions in both test areas will be evaluated 15 to 30 minutes after patch removal and graded according to the International Contact Dermatitis Research Group (ICDRG) criteria. Skin reactions will be graded according to the International Contact Dermatitis Research Group (ICDRG) criteria, ranging from 0 (negative reaction) to 4 (strong positive reaction). Higher grades indicate greater skin reactivity.

    Time frame: Day 30 and Day 32

07

Study locations

1 site
  • Grupo Medcin
    Osasco, São Paulo 06023-070, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2026 to primary completion in Aug 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2026
First posted
Sep 1, 2026
StartActual
Jul 13, 2026
Primary completionActual
Aug 25, 2026
CompletionActual
Aug 25, 2026
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07797192
Responsible party
Sponsor
First posted
Sep 1, 2026
Start date
Jul 13, 2026
Primary completion
Aug 25, 2026
Completion
Aug 25, 2026
Last update
Sep 16, 2026

Study contacts

Sergio Schalka
principal investigator · Grupo Medcin

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion